FCA review of competition in the wholesale markets
By Richard Ellis
The Financial Conduct Authority (FCA) has announced a review of competition in the wholesale financial markets.
The FCA is concerned that there may be areas within the wholesale financial markets where competition is weak or not working properly. One of the FCA’s objectives is to promote effective competition in financial markets so it is duty bound to explore these concerns and try to remedy any problems.
The areas of the wholesale sector that will be covered by this review are: (a) markets and market infrastructure; (b) asset management and fund services; (c) investment banking; and (d) corporate banking…
Click on the link below to read the rest of the Wragge Lawrence Graham & Co briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
Ruling on an application for specific disclosure could have big implications in the early stages of procurement disputes.
Hospira v Genentech III: Swiss form claim obvious in view of paper reporting the existence of Phase III trial
Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira’s continued efforts to knock out Genentech’s patents.